azacitidine has been researched along with Lymphoma, Large B-Cell, Diffuse in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Alizadeh, AA; Beaven, AW; Brem, EA; Caimi, PF; Cerchietti, L; Dillon, H; Friedberg, JW; Henry, NL; Laubach, C; LeBlanc, M; Li, H; Little, RF; Olin, R; Smith, SM | 1 |
| Ishiguro, C; Kawashiri, A; Kurokawa, T; Maeda, Y; Mochizuki, K; Nakagawa, SI | 1 |
| de Graaf, IJ; Heemskerk, MHM; Kroonen, JS; Kumar, S; Remst, DFG; Vertegaal, ACO; Wouters, AK | 1 |
| Byun, JM; Hong, J; Kim, D; Kim, TK; Koh, Y; Liu, J; Min, S; Park, E; Park, J; Shin, DY; Yoon, SS | 1 |
| Bartlett, NL; Cerchietti, L; Chavez, JC; Drew, J; Jones, J; LaCasce, AS; Leonard, JP; Martin, P; Mulvey, E; Reagan, JL; Revuelta, MV; Smith, SM; Wu, C | 1 |
| Hiraga, J; Kagami, Y; Kato, H; Narita, M; Suzuki, N; Takagi, Y; Ujihira, N | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| de Fabritiis, P; Fratoni, S; Giovannini, M; Niscola, P; Palombi, M; Perrotti, A; Scaramucci, L; Tendas, A; Trawinska, MM | 1 |
| Banerjee, S; Borden, KL; Cerchietti, L; Chadburn, A; Clozel, T; Culjkovic, B; Elstrom, RL; Gascoyne, RD; Godley, LA; Inghirami, G; Kormaksson, M; Leonard, JP; Leser, M; Martin, P; Melnick, A; Scott, DW; Shaknovich, R; Tabbo, F; Tam, W; Vasanthakumar, A; Wyman, S; Yang, S | 1 |
| Berger, F; Bertoni, F; Cavalli, F; Cogliatti, S; Forconi, F; Gaidano, G; Gattei, V; Kwee, I; Lucioni, M; Marasca, R; Mensah, AA; Orlandi, EM; Rinaldi, A; Rossi, D; Zucca, E | 1 |
| Gartenhaus, RB; Steinhardt, JJ | 1 |
| McCarthy, N | 1 |
| Jiang, Z; Kuo, PY; Leshchenko, VV; Parekh, S; Thirukonda, VK | 1 |
| Bai, Y; Jiang, X; Ren, G; Shi, H; Shi, Y; Wang, J; Wang, L; Zhang, X; Zhou, R | 1 |
| Hu, ZL; Li, J; Yang, YL; Zhang, F; Zhang, J; Zhang, YW; Zhou, LL; Zhu, JF | 1 |
| Jing, H; Li, Z; Wang, J; Wang, W; Wang, Y; Zhang, Z; Zhu, M | 1 |
| Aiba, K; Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Nagasaki, E | 1 |
| Ahn, H; Cerchietti, L; Elstrom, R; Furman, R; Leonard, J; Martin, P; Marullo, R; Patel, J; Pera, B; Ruan, J; Tang, T; Yang, SN | 1 |
| Amengual, J; Bhagat, G; Kalac, M; Leshchenko, VV; Marchi, E; O'Connor, OA; Parekh, S; Scotto, L; Seshan, VE; Temkin, AM; Tycko, B; Ulahannan, N | 1 |
| Harada, M; Ishimaru, F; Ito, S; Ogama, Y; Ouchida, M; Shimizu, K; Shiote, Y; Takimoto, H; Tanimoto, M; Yoshino, T | 1 |
| Agrelo, R; Artiga, MJ; Espada, J; Esteller, M; Fraga, MF; Pérez-Rosado, A; Piris, MA; Rodriguez, M; Sanchez-Aguilera, A; Setien, F | 1 |
| Kinoshita, T; Li, Y; Murohara, T; Nagai, H; Ohashi, H; Ohno, T; Saito, H | 1 |
| Amin, HM; Franko, B; Frantz, C; Han, Y; Lai, R; Lee, J; Lin, Q | 1 |
4 trial(s) available for azacitidine and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospectiv
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Frailty; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prospective Studies; Rituximab | 2022 |
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Risk Factors; Rituximab; Survival Rate; Vincristine | 2022 |
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; DNA Damage; DNA Methylation; DNA Modification Methylases; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; RNA Interference; RNA, Small Interfering; Smad1 Protein; Young Adult | 2013 |
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Treatment Outcome; Vorinostat | 2016 |
19 other study(ies) available for azacitidine and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia.
Topics: Antilymphocyte Serum; Azacitidine; Busulfan; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; HLA Antigens; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Positron Emission Tomography Computed Tomography; Tacrolimus; Transplantation Conditioning | 2022 |
Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies.
Topics: Azacitidine; Burkitt Lymphoma; Cell Line, Tumor; Decitabine; DNA; Hematologic Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Sumoylation | 2023 |
Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Endogenous Retroviruses; Epigenesis, Genetic; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Rituximab | 2023 |
EBV-positive Diffuse Large B-cell Lymphoma as a Secondary Malignancy Arising in a Myelodysplastic Syndrome Patient who Was Treated with Azacitidine.
Topics: Azacitidine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary | 2017 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab-bendamustine regimen combined to hypomethylating therapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Female; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2013 |
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.
Topics: Azacitidine; Cell Cycle; Cell Transformation, Neoplastic; Cluster Analysis; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Epigenomics; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplastic Stem Cells; Oncostatin M; Promoter Regions, Genetic; Reproducibility of Results | 2013 |
Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.
Topics: Azacitidine; DNA Methylation; DNA Modification Methylases; Humans; Lymphoma, Large B-Cell, Diffuse | 2013 |
Epigenetics: Showing a more sensitive side.
Topics: Azacitidine; DNA Methylation; DNA Modification Methylases; Humans; Lymphoma, Large B-Cell, Diffuse | 2013 |
Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; Disease Models, Animal; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genomics; Humans; Lymphoma, Large B-Cell, Diffuse; Promoter Regions, Genetic; Temozolomide; Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
[Significance of expression and promoter methylation of LITAF gene in B-cell lymphoma].
Topics: Adult; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Silencing; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Nuclear Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Transcription Factors | 2014 |
Methylation contributes to imbalance of PRDM1α/PRDM1bβ expression in diffuse large B-cell lymphoma.
Topics: Azacitidine; Cell Line, Tumor; Cluster Analysis; CpG Islands; DNA Methylation; Down-Regulation; Epigenomics; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Loci; Humans; Lymphoma, Large B-Cell, Diffuse; Male; MicroRNAs; Positive Regulatory Domain I-Binding Factor 1; Promoter Regions, Genetic; Protein Isoforms; Repressor Proteins; Transcription, Genetic | 2015 |
Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Death-Associated Protein Kinases; DNA Methylation; Epigenesis, Genetic; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Proteins; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 13; Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 2016 |
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Rituximab; Thalidomide; Up-Regulation | 2016 |
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
Topics: Acetylation; Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Panobinostat; Xenograft Model Antitumor Assays | 2011 |
Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas.
Topics: Azacitidine; Cadherins; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Prognosis; Promoter Regions, Genetic; RNA, Messenger | 2004 |
Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; CpG Islands; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lamin Type A; Lymph Nodes; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Promoter Regions, Genetic; Survival Rate; Tumor Cells, Cultured | 2005 |
Aberrant DNA demethylation in promoter region and aberrant expression of mRNA of PAX4 gene in hematologic malignancies.
Topics: Azacitidine; Cell Line; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Profiling; Homeodomain Proteins; Humans; Lymphadenitis; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Paired Box Transcription Factors; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity | 2006 |
Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Topics: Anaplastic Lymphoma Kinase; Apoptosis; Azacitidine; Base Sequence; Blotting, Western; Cell Cycle; Cell Line; Decitabine; DNA Primers; Down-Regulation; Doxorubicin; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinase 3; Lymphoma, Large B-Cell, Diffuse; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Receptor Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor | 2006 |